Financial reports
10-K
2023 FY
Annual report
28 Mar 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
10-Q
2023 Q1
Quarterly report
12 May 23
10-K
2022 FY
Annual report
24 Mar 23
10-Q
2022 Q3
Quarterly report
10 Nov 22
10-Q
2022 Q2
Quarterly report
12 Aug 22
10-Q
2022 Q1
Quarterly report
13 May 22
10-K
2021 FY
Annual report
29 Mar 22
10-Q
2021 Q3
Quarterly report
15 Nov 21
Current reports
8-K
Humacyte Fourth Quarter and Year End 2023 Financial Results and Business Update
22 Mar 24
8-K
Humacyte, Inc. Announces Proposed Public Offering of Common Stock
4 Mar 24
8-K
Other Events
29 Feb 24
8-K
Human Acellular Vessel™ (HAV™) Biologics License Application Granted Priority Review by U.S. FDA for the Treatment of Vascular Trauma
9 Feb 24
8-K
Other Events
12 Dec 23
8-K
Humacyte Third Quarter 2023 Financial Results and Business Update
9 Nov 23
8-K
Humacyte Announces Positive Top Line Results from Phase 2/3 Trial of Human Acellular Vessel™ (HAV™) in Treatment of Patients with Vascular Trauma
12 Sep 23
8-K
Humacyte Second Quarter 2023 Financial Results and Business Update
14 Aug 23
8-K
Humacyte Completes Enrollment in Phase 2/3 Trial of
26 Jul 23
8-K
Submission of Matters to a Vote of Security Holders
8 Jun 23
Registration and prospectus
S-8
Registration of securities for employees
28 Mar 24
424B5
Prospectus supplement for primary offering
1 Mar 24
424B5
Prospectus supplement for primary offering
29 Feb 24
424B3
Prospectus supplement
22 Jun 23
S-3
Shelf registration
9 Jun 23
POS AM
Prospectus update (post-effective amendment)
12 Sep 22
424B3
Prospectus supplement
9 Sep 22
424B3
Prospectus supplement
9 Sep 22
S-3
Shelf registration
1 Sep 22
S-3
Shelf registration
1 Sep 22
Other
EFFECT
Notice of effectiveness
22 Jun 23
CORRESP
Correspondence with SEC
16 Jun 23
UPLOAD
Letter from SEC
15 Jun 23
EFFECT
Notice of effectiveness
15 Sep 22
EFFECT
Notice of effectiveness
12 Sep 22
EFFECT
Notice of effectiveness
12 Sep 22
CORRESP
Correspondence with SEC
7 Sep 22
CORRESP
Correspondence with SEC
7 Sep 22
UPLOAD
Letter from SEC
7 Sep 22
UPLOAD
Letter from SEC
7 Sep 22
Ownership
SC 13D/A
Niklason Laura E
8 Mar 24
SC 13D/A
FRESENIUS MEDICAL CARE HOLDINGS INC /NY/
7 Mar 24
4
William John Scheessele
12 Dec 23
4
Heather Ledbetter Prichard
12 Dec 23
4
Shamik J Parikh
12 Dec 23
4
Yang Cao
12 Dec 23
4
Dale A. Sander
12 Dec 23
4
Brady W Dougan
12 Dec 23
4
Laura E Niklason
12 Dec 23
SC 13D/A
FRESENIUS MEDICAL CARE HOLDINGS INC /NY/
1 Dec 23